[go: up one dir, main page]

WO2006127987A3 - Treatment of eye disorders with sirtuin modulators - Google Patents

Treatment of eye disorders with sirtuin modulators Download PDF

Info

Publication number
WO2006127987A3
WO2006127987A3 PCT/US2006/020406 US2006020406W WO2006127987A3 WO 2006127987 A3 WO2006127987 A3 WO 2006127987A3 US 2006020406 W US2006020406 W US 2006020406W WO 2006127987 A3 WO2006127987 A3 WO 2006127987A3
Authority
WO
WIPO (PCT)
Prior art keywords
sirtuin modulators
eye disorders
treatment
sirtuin
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/020406
Other languages
French (fr)
Other versions
WO2006127987A2 (en
Inventor
Michael Milburn
Christoph H Westphal
David J Livingston
Philip Lambert
Karl D Normington
Peter Elliott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sirtris Pharmaceuticals Inc
Original Assignee
Sirtris Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirtris Pharmaceuticals Inc filed Critical Sirtris Pharmaceuticals Inc
Priority to CA002609549A priority Critical patent/CA2609549A1/en
Priority to JP2008513752A priority patent/JP2008542296A/en
Priority to EP06784483A priority patent/EP1928440A2/en
Priority to AU2006249816A priority patent/AU2006249816A1/en
Publication of WO2006127987A2 publication Critical patent/WO2006127987A2/en
Anticipated expiration legal-status Critical
Publication of WO2006127987A3 publication Critical patent/WO2006127987A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Sirtuin modulators, particularly sirtuin activators, are useful in treating vision impairment. In general, the sirtuin modulators inhibit the progression of vision impairment resulting from various eye disorders. The invention also includes pharmaceutically acceptable formulations of sirtuin modulators, particular ophthalmically acceptable formulations.
PCT/US2006/020406 2005-05-25 2006-05-24 Treatment of eye disorders with sirtuin modulators Ceased WO2006127987A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002609549A CA2609549A1 (en) 2005-05-25 2006-05-24 Treatment of eye disorders with sirtuin modulators
JP2008513752A JP2008542296A (en) 2005-05-25 2006-05-24 Treatment of eye disorders with sirtuin activators
EP06784483A EP1928440A2 (en) 2005-05-25 2006-05-24 Treatment of eye disorders with sirtuin modulators
AU2006249816A AU2006249816A1 (en) 2005-05-25 2006-05-24 Treatment of eye disorders with sirtuin modulators

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US68425205P 2005-05-25 2005-05-25
US60/684,252 2005-05-25
US73155005P 2005-10-28 2005-10-28
US60/731,550 2005-10-28
US78835806P 2006-03-30 2006-03-30
US60/788,358 2006-03-30

Publications (2)

Publication Number Publication Date
WO2006127987A2 WO2006127987A2 (en) 2006-11-30
WO2006127987A3 true WO2006127987A3 (en) 2008-04-17

Family

ID=37307152

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/020406 Ceased WO2006127987A2 (en) 2005-05-25 2006-05-24 Treatment of eye disorders with sirtuin modulators

Country Status (5)

Country Link
EP (1) EP1928440A2 (en)
JP (1) JP2008542296A (en)
AU (1) AU2006249816A1 (en)
CA (1) CA2609549A1 (en)
WO (1) WO2006127987A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
US20110009496A1 (en) * 2008-01-08 2011-01-13 Sirtris Pharmaceuticas, Inc. Resveratrol formulations
JP5425891B2 (en) 2008-05-01 2014-02-26 サートリス ファーマシューティカルズ， インコーポレイテッド Quinolines and related analogs as sirtuin modulators
KR20110036602A (en) 2008-07-03 2011-04-07 서트리스 파마슈티컬즈, 인코포레이티드 Benzimidazole and related analogs as sirtuin modulators
JP5743326B2 (en) 2008-09-29 2015-07-01 サートリス ファーマシューティカルズ， インコーポレイテッド Chromenone analog as a sirtuin modulator
CN102307568B (en) 2009-02-04 2014-12-24 帝斯曼知识产权资产管理有限公司 Resvertrol compositions
GB0903688D0 (en) * 2009-03-03 2009-04-15 Agentis Suppliments Composition
KR20120092141A (en) 2009-10-29 2012-08-20 서트리스 파마슈티컬즈, 인코포레이티드 Bicyclic pyridines and analogs as sirtuin modulators
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
WO2013033513A1 (en) 2011-08-31 2013-03-07 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
US8916528B2 (en) 2011-11-16 2014-12-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
EP2814496B1 (en) 2012-02-17 2018-04-11 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
SG11201405895UA (en) 2012-03-27 2014-10-30 Cempra Pharmaceuticals Inc Parenteral formulations for administering macrolide antibiotics
JP5955750B2 (en) * 2012-11-20 2016-07-20 株式会社東洋新薬 Skin preparation
ES2952032T3 (en) 2013-03-15 2023-10-26 Washington University St Louis Administration of nicotinamide mononucleotide in the treatment of dry eye
WO2015138992A1 (en) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
US20160374918A1 (en) * 2015-06-29 2016-12-29 The Procter & Gamble Company Encapsulated skin care agent
US20160374908A1 (en) * 2015-06-29 2016-12-29 The Procter & Gamble Company Skin care composition and methods of using the same
WO2017004102A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container
BR112018013757B1 (en) 2016-01-11 2021-11-09 The Procter & Gamble Company METHOD FOR THE TREATMENT OF A SKIN CONDITION AND COMPOSITIONS FOR IT
HUE057052T2 (en) 2016-02-18 2022-04-28 Invirsa Inc Therapeutic use of 5'-adenosine diphosphate ribose (ADPR)
WO2018030389A1 (en) * 2016-08-08 2018-02-15 学校法人 慶應義塾 Use of nad-related metabolite
ES2955713T3 (en) * 2016-09-13 2023-12-05 Megumi Tanaka Visual function improvement agent, and method for improving visual function
EP3538083B1 (en) * 2016-11-14 2024-07-10 NeuVision Development LLC Formulations for the treatment of ocular surface diseases and related methods
WO2018165266A1 (en) * 2017-03-07 2018-09-13 Cempra Pharmaceuticals, Inc. Compositions and methods for treating dry eye diseases
CN110785161B (en) 2017-06-23 2023-06-20 宝洁公司 Compositions and methods for improving skin appearance
JP7242696B2 (en) 2018-03-27 2023-03-20 インバーサ， インコーポレイテッド Method of using 5'-adenosine diphosphate ribose (ADPR)
KR20210011964A (en) 2018-07-03 2021-02-02 더 프록터 앤드 갬블 캄파니 How to treat a skin condition
ES2989969T3 (en) * 2019-06-25 2024-11-28 Senju Pharma Co Novel Use of Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR)
WO2021247496A1 (en) 2020-06-01 2021-12-09 The Procter & Gamble Company Method of improving penetration of a vitamin b3 compound into skin
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
WO1989006536A1 (en) * 1988-01-19 1989-07-27 Moses Judah Folkman Growth inhibiting agent and the use thereof
US4983586A (en) * 1987-12-30 1991-01-08 University Of Florida Pharmaceutical formulations for parenteral use
WO1994015582A1 (en) * 1993-01-05 1994-07-21 Javitt Jonathan C Topical compositions for the eye comprising a beta-cyclodextrin derivative and a carbonic anhydrase inhibitor
WO2000038620A2 (en) * 1998-12-24 2000-07-06 1333366 Ontario Inc. A composition useful to treat periodontal disease
JP2000344622A (en) * 1999-03-31 2000-12-12 Sunstar Inc Stabilization of stilbenic compound and plant extract containing the same, and food, medicine, cosmetic or oral cavity preparation stably compounded with stilbenic compound and plant extract containing the same
CA2312505A1 (en) * 2000-06-27 2001-12-27 1333366 Ontario Inc. Resveratrol compositions for topical use in the treatment of oral diseases and infections
WO2002032410A2 (en) * 2000-10-19 2002-04-25 Imperial College Innovations Limited Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders
CN1500479A (en) * 2002-11-15 2004-06-02 董英杰 resveratrol , piceid and its derivative and its preparation
WO2005002555A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Sirt1 modulators for manipulating cell/organism lifespan/stress response
WO2005004877A1 (en) * 2003-07-01 2005-01-20 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
WO2005068484A1 (en) * 2004-01-19 2005-07-28 Merck Patent Gmbh Flavonoid complexes comprising cyclodextrins
EP1621199A1 (en) * 2003-04-18 2006-02-01 Advanced Medicine Research Institute Remedies for diseases to be applied to eye

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2190771B2 (en) * 2002-01-24 2004-03-01 Univ Alicante PROCEDURE FOR THE PRODUCTION OF RESVERATROL IN CELL CULTURES.
JP2003252760A (en) * 2002-03-01 2003-09-10 Mitsubishi Pharma Corp Retinal disease therapeutic and / or prophylactic agent
AU2004279644A1 (en) * 2003-10-10 2005-04-21 Resverlogix Corp. Treatment of diseases associated with the egr-1 enhancer element
US7776326B2 (en) * 2004-06-04 2010-08-17 Washington University Methods and compositions for treating neuropathies
CA2595159A1 (en) * 2005-01-13 2006-07-20 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US4983586A (en) * 1987-12-30 1991-01-08 University Of Florida Pharmaceutical formulations for parenteral use
WO1989006536A1 (en) * 1988-01-19 1989-07-27 Moses Judah Folkman Growth inhibiting agent and the use thereof
WO1994015582A1 (en) * 1993-01-05 1994-07-21 Javitt Jonathan C Topical compositions for the eye comprising a beta-cyclodextrin derivative and a carbonic anhydrase inhibitor
WO2000038620A2 (en) * 1998-12-24 2000-07-06 1333366 Ontario Inc. A composition useful to treat periodontal disease
JP2000344622A (en) * 1999-03-31 2000-12-12 Sunstar Inc Stabilization of stilbenic compound and plant extract containing the same, and food, medicine, cosmetic or oral cavity preparation stably compounded with stilbenic compound and plant extract containing the same
CA2312505A1 (en) * 2000-06-27 2001-12-27 1333366 Ontario Inc. Resveratrol compositions for topical use in the treatment of oral diseases and infections
WO2002032410A2 (en) * 2000-10-19 2002-04-25 Imperial College Innovations Limited Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders
CN1500479A (en) * 2002-11-15 2004-06-02 董英杰 resveratrol , piceid and its derivative and its preparation
EP1621199A1 (en) * 2003-04-18 2006-02-01 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
WO2005002555A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Sirt1 modulators for manipulating cell/organism lifespan/stress response
WO2005004877A1 (en) * 2003-07-01 2005-01-20 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
WO2005068484A1 (en) * 2004-01-19 2005-07-28 Merck Patent Gmbh Flavonoid complexes comprising cyclodextrins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIRRELL MARK A ET AL: "Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-kappa B-independent mechanism", FASEB JOURNAL, vol. 19, no. 2, February 2005 (2005-02-01), XP002466174, ISSN: 0892-6638 *
CHAUMEIL J C: "MICRONIZATION: A METHOD OF IMPROVING THE BIOAVAILABILITY OF POORLY SOLUBLE DRUGS", METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, PROUS, BARCELONA, ES, vol. 20, no. 3, April 1998 (1998-04-01), pages 211 - 215, XP009048140, ISSN: 0379-0355 *
DATABASE WPI Week 200466, Derwent World Patents Index; AN 2004-669421, XP002406704 *
PATENT ABSTRACTS OF JAPAN *

Also Published As

Publication number Publication date
EP1928440A2 (en) 2008-06-11
CA2609549A1 (en) 2006-11-30
AU2006249816A1 (en) 2006-11-30
WO2006127987A2 (en) 2006-11-30
JP2008542296A (en) 2008-11-27

Similar Documents

Publication Publication Date Title
WO2006105403A3 (en) Treatment of eye disorders with sirtuin modulators
WO2006127987A3 (en) Treatment of eye disorders with sirtuin modulators
WO2008029276A3 (en) Compositions and methods for the treatment of ophthalmic disease
WO2004108133A3 (en) Modulators of vr1 receptor
WO2006039467A3 (en) Biomedical devices containing amphiphilic block copolymers
WO2005123093A3 (en) Ophthalmic formulations including selective alpha 1 antagonists
IL188789A0 (en) Formulation and method for administration of ophthalmologically active agents
WO2005091853A3 (en) Methods and compositions for treating il-13 related pathologies
WO2008002976A3 (en) Translating multifocal ophthalmic lenses
DE502005011119D1 (en)
DK1509121T3 (en) Ocular viewer for the treatment of eye disorders
MX2009012645A (en) Formulations and methods for treating dry eye.
WO2007011874A3 (en) Formulation and method for administration of ophthalmologically active agents
WO2006060618A3 (en) Topical nepafenac formulations
WO2006127900A3 (en) Tl1a in the treatment of disease
WO2006124713A3 (en) 4-biarylyl-1-phenylazetidin-2-ones
WO2007120817A3 (en) Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear
AU2003210597A1 (en) Methods for treating eye disorders
WO2003005941A3 (en) Insert for the treatment of dry eye
WO2005099702A3 (en) R(-)-11-hydroxyaporphine derivatives and uses thereof
WO2007058935A3 (en) Ophthalmic composition for dry eye therapy
WO2006092741A3 (en) Treatment of inflammatory disorders with praziquantel
TW200609559A (en) Contact lenses and methods for their design
WO2005097164A3 (en) Use of cyclosporins for treatment of cerebral ischemia and brain and spinal cord injury
WO2006012521A3 (en) Treatment for ocular disease

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006784483

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006249816

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2008513752

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2609549

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU